102
E. Arons & R. J. Kreitman
Table I. Complete remission (or clearing of bone marrow biopsy with resolutions of blood counts) achieved by immunotherapy with or without chemotherapy for HCLv or VH4-34þ HCL.
Open
Patient ID VH Diagnosis Treatment* BL14
BL18 BL26 BH32 RG01 RG02 RG04
VH4-31 HCLv BL22 VH4-34 HCLv BL22 VH4-34 HCLv BL22 VH4-34 HCLc BL22
clinical trial 07-C-0130
07-C-0130 07-C-0130 07-C-0130
Unknown HCLv CDAR 09-C-0005 Unknown HCLv CDAR 09-C-0005 VH4-34 HCLv CDAR 09-C-0005
*HA22, also called CAT-8015 or moxetumomab pasudotox, is a higher-affinity version of BL22 which is now undergoing testing for HCL, protocol 07-C-0130. HCLv, hairy cell leukemia variant; HCLc, classic hairy cell leukemia; CDAR, cladribine þ rituximab.
induce complete remission (CR) in HCLv. As shown in Table I, we have also observed frequent complete remissions in patients treated with monoclonal anti- body (mAb)-based therapy, including BL22 [13,14] and also the combination of rituximab and cladribine (CDAR) [15]. We believe it is potentially valuable to determine the molecular status of patients with HCL, and also to develop new therapies for patients who have recognized poor-prognosis variants.
Acknowledgements
This work was supported in part by the National Cancer Institute, Intramural Program. A portion of this research was originally published in Blood by Arons et al. (see ref 9).
Potential conflict of interest: Disclosure forms provided by the authors are available with the full text of this article at
www.informahealthcare.com/lal.
References
1. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproli- ferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res 1980;4:547–559.
2. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001;15:184– 186.
3. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
4. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003;16: 41–56.
5. Arons E, Margulies I, Sorbara L, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone- specific polymerase chain reaction. Clin Cancer Res 2006;12:2804–2811.
6. Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy cell leukemia. Br J Haematol 2006;133:504–512.
7. Martin-Jimenez P, Garcia-Sanz R, Gonzalez D, et al. Mole- cular characterization of complete and incomplete immuno- globulin heavy chain gene rearrangements in hairy cell leukemia. Clin Lymphoma Myeloma 2007;7:573–579.
8. Forconi F, Sozzi E, Rossi D, et al. Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica 2008;93: 697–705.
9. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-
34þ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687–4695.
10. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008;111:1524– 1533.
11. Brezinschek HP, Foster SJ, Brezinschek RI, Dorner T, Domiati-Saad R, Lipsky PE. Analysis of the human VH gene repertoire. Differential effects of selection and somatic
12. Rettig MB, Vescio RA, Cao J, et al. VH gene usage in multiple myeloma: complete absence of the VH4.21 (VH4-34) gene. Blood 1996;87:2846–2852.
hypermutation on human peripheral CD5(þ)/IgMþ and CD5(7)/IgMþ B cells. J Clin Invest 1997;99:2488–2501.
13. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemother- apy-resistant hairy-cell leukemia. N Engl J Med 2001;345: 241–247.
14. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27: 2983–2990.
15. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658–4662.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122